Related by context. All words. (Click for frequent words.) 71 elotuzumab 70 registrational 70 lumiliximab 69 PXD# 69 romidepsin 69 alvespimycin 69 perifosine 69 obatoclax 68 CIMZIA TM 68 pomalidomide 68 enzastaurin 68 HGS ETR1 68 forodesine 68 bendamustine 68 FOLOTYN 68 HuMax CD4 67 deforolimus 67 atacicept 67 IMGN# 67 RITUXAN 67 PROMACTA 67 tocilizumab 67 docetaxel Taxotere R 67 tanespimycin 67 ofatumumab HuMax CD# 67 Fludara 67 HGS# 67 ganetespib 67 Phase 2b trial 67 sapacitabine 66 valopicitabine 66 ZEVALIN 66 Phase 2a trial 66 talactoferrin 66 HER2 positive metastatic breast 66 Phase 1b 66 clofarabine 66 ELACYT 66 Dacogen injection 66 phase IIa clinical 66 Traficet EN 66 Amrubicin 66 EOquin TM 66 Phase Ib 66 custirsen 66 celgosivir 66 Marqibo 66 eniluracil 66 axitinib 66 CHOP chemotherapy 66 blinatumomab 66 confirmatory Phase III 65 Phase IIIb clinical 65 oral ridaforolimus 65 Cloretazine R VNP#M 65 Amigal 65 ocrelizumab 65 decitabine 65 glufosfamide 65 docetaxel chemotherapy 65 JAK inhibitor 65 Zerenex 65 VELCADE 65 TORISEL 65 relapsed refractory multiple myeloma 65 phase IIb clinical 65 metastatic CRC 65 HuMax CD# 65 Cethrin 65 phase Ib 65 otelixizumab 65 abiraterone acetate 65 rilonacept 65 sunitinib malate 65 OMAPRO 65 cilengitide 65 Firazyr 65 IMA# 65 ularitide 65 vidofludimus 65 zalutumumab 65 rituximab 65 relapsed multiple myeloma 65 methylnaltrexone 65 ASA# 64 indolent NHL 64 dose escalation trial 64 Phase Ib study 64 SNT MC# 64 Phase 1b trial 64 CR# vcMMAE 64 TREANDA 64 pralatrexate 64 BAY #-# 64 eltrombopag 64 eculizumab 64 Imprime PGG 64 Restanza 64 EndoTAG TM -1 64 brentuximab vedotin 64 belinostat 64 HuMax EGFr 64 Velcade bortezomib 64 pertuzumab 64 HuLuc# 64 Plicera 64 daclizumab 64 pazopanib 64 azacitidine 64 regorafenib 64 MGCD# [001] 64 veltuzumab 64 SUTENT 64 standard chemotherapy regimen 64 zanolimumab 64 Evoltra TM 64 registrational trial 64 Treanda 64 Targretin 64 EOquin 64 Taxotere ® 64 multiple myeloma MM 64 tamibarotene 64 refractory CLL 64 BEXXAR 64 ponatinib 64 albinterferon alfa 2b 64 YONDELIS 64 vinorelbine 64 aflibercept 64 NXL# 64 Panzem R NCD 64 L BLP# 64 lintuzumab 64 cetrorelix 64 biologic therapy 63 ridaforolimus 63 mapatumumab 63 adecatumumab 63 HCD# [002] 63 Alzhemed TM 63 placebo controlled Phase 63 Azedra 63 panitumumab 63 Genasense 63 resminostat 63 NEBIDO 63 posaconazole 63 MAA submission 63 MabThera Rituxan 63 elacytarabine 63 BRIM2 63 brivaracetam 63 MabCampath 63 dirucotide 63 Ofatumumab 63 maribavir 63 carfilzomib 63 fostamatinib 63 nab paclitaxel 63 teriflunomide 63 Proxinium TM 63 PEG SN# 63 Aptivus ® 63 amrubicin 63 subcutaneous formulation 63 ILLUMINATE 63 oral prodrug 63 lesinurad 63 Phase 2b study 63 teduglutide 63 Clolar 63 tesmilifene 63 pradefovir 63 ceftaroline 63 Cladribine Tablets 63 CoFactor 63 Jevtana 63 lapatinib 63 picoplatin 63 PDE4 inhibitor 63 ATL# [001] 63 Bezielle 63 R#/MEM # 63 Phase III TRIST 63 TELCYTA 63 AGGRASTAT ® 63 galiximab 63 RSD# oral 63 Tarceva TM 63 Targretin capsules 63 Phenoptin 63 Nanobody 63 telaprevir dosed 63 dose escalation 63 XmAb# 63 satraplatin 63 Phase Ib clinical 62 mertansine 62 torezolid phosphate 62 Phase Ib II 62 Revlimid lenalidomide 62 MAGE A3 ASCI 62 RG# [001] 62 Tarceva erlotinib 62 vandetanib 62 goserelin 62 dose escalation clinical 62 Sym# 62 Virulizin ® 62 OXi# 62 dabigatran etexilate 62 Rituximab 62 Bicifadine 62 relapsing remitting multiple sclerosis 62 phase IIb trial 62 dacetuzumab 62 tipranavir 62 FOLFIRI 62 Onrigin 62 INCB# [001] 62 HRPC 62 Taxotere R 62 BCX# 62 TYKERB 62 Allovectin 7 62 LEUKINE 62 rALLy clinical trial 62 pivotal Phase III 62 pegfilgrastim 62 Aplidin 62 romiplostim 62 afatinib 62 Ceflatonin 62 NVA# 62 baminercept 62 ACTEMRA 62 heavily pretreated 62 velaglucerase alfa 62 Urocidin 62 TOCOSOL Paclitaxel 62 TRISENOX 62 Aflibercept 62 PEG Interferon lambda 62 follicular NHL 62 Troxatyl 62 imetelstat 62 LUX Lung 62 TroVax 62 oral deforolimus 62 Clavis Pharma 62 Phase IIa trial 62 carboplatin paclitaxel 62 AZILECT R 62 fipamezole 62 sunitinib 62 OZURDEX ® 62 ixabepilone 62 phase IIb 62 low dose cytarabine 62 Phase IIa clinical 62 CA4P 62 alvimopan 62 Allovectin 7 ® 62 Phase 2b clinical 62 velafermin 62 omacetaxine 62 BiovaxID 62 AQ4N 62 golimumab 62 histone deacetylase HDAC inhibitor 62 OvaRex ® MAb 62 GFT# 62 Shigamabs ® 62 tremelimumab 62 Altastaph 62 Triapine 62 HGS ETR2 62 multicenter Phase 62 huC# DM4 62 Virulizin R 62 reslizumab 62 entinostat 61 relapsed refractory 61 Cloretazine 61 CytoFab 61 CytoFabTM 61 phase IIa 61 L MTP PE 61 DU #b 61 APTIVUS r 61 epratuzumab 61 seliciclib 61 ONTAK 61 dose escalation Phase 61 Fibrillex TM 61 Herceptin trastuzumab 61 evaluating tivozanib 61 REMICADE ® 61 PSMA ADC 61 FOLOTYN ® 61 CD# antibody [001] 61 KRN# 61 Xcytrin 61 Viramidine 61 nitazoxanide 61 PRT# 61 sargramostim 61 ADVEXIN 61 OncoVEX GM CSF 61 XL# [003] 61 dose cohorts 61 lomitapide 61 bevacizumab Avastin ® 61 CTCE 61 ERBITUX 61 adecatumumab MT# 61 neratinib 61 LymphoStat B 61 cangrelor 61 Nexavar sorafenib 61 Zenvia ™ 61 monotherapy 61 figitumumab 61 thymalfasin 61 Clolar ® 61 previously untreated follicular 61 ISTODAX 61 dasatinib 61 Nexavar ® 61 Phase IIa trials 61 Ixempra 61 investigational compound 61 vorinostat 61 vicriviroc 61 Alocrest 61 IRESSA 61 Insegia 61 xanthine oxidase inhibitor 61 Torisel 61 rindopepimut 61 metastatic hormone refractory 61 Perifosine 61 ADVANCE PD 61 TMC# [002] 61 refractory metastatic colorectal cancer 61 diabetic neuropathic pain 61 palonosetron 61 randomized Phase 61 Phase 1b clinical 61 Phase #/#a 61 TELINTRA 61 AeroLEF TM 61 Mylotarg 61 PEG PAL 61 VELCADE melphalan 61 adalimumab 61 acyclovir Lauriad R 61 VPRIV 61 canakinumab 61 Phase III randomized controlled 61 lenalidomide Revlimid R 61 refractory multiple myeloma 61 UVIDEM 61 sorafenib Nexavar 61 EFAPROXYN 61 chlorambucil 61 CVP chemotherapy 61 MoxDuo IR 61 trabedersen 61 AZILECT ® 61 Rituxan 61 dacarbazine 61 Dacogen 61 Reolysin 61 Durezol 61 Hedgehog antagonist 61 Gleevec imatinib mesylate 61 iclaprim 61 bicifadine 61 FOLFOX chemotherapy 61 omacetaxine mepesuccinate 61 dextromethorphan quinidine 61 linaclotide 61 Phase IIb clinical 61 CIMZIA ™ 61 Erbitux cetuximab 61 INCB# [002] 61 Phase 2b 61 bazedoxifene 61 sorafenib 61 FTY# 61 relapsed MM 61 fidaxomicin 60 trastuzumab Herceptin R 60 PI3K/Akt pathway inhibitor 60 PRECiSE 60 ZYBRESTAT 60 Abiraterone acetate 60 pemetrexed 60 Campath 60 edoxaban 60 SUCCEED trial 60 viral kinetics 60 SPRYCEL ® 60 dimebon 60 ARIKACE 60 Phase III clinical 60 IIa trial 60 Folotyn 60 bosentan 60 ONCASPAR 60 Bronchitol 60 TYZEKA 60 brentuximab vedotin SGN 60 ATL/TV# 60 evaluating Xcytrin 60 ascending dose 60 registrational studies 60 Cimzia ® 60 relapsed ovarian cancer 60 Neulasta ® 60 adalimumab Humira 60 nilotinib 60 AP# [003] 60 T DM1 60 cutaneous T cell 60 incyclinide 60 AVASTIN 60 PDX pralatrexate 60 Cotara 60 trabectedin 60 randomized Phase III 60 voreloxin 60 REVLIMID 60 BRAF inhibitor 60 sorafenib tablets 60 Northera 60 pivotal Phase 60 Phase #b/#a 60 NP2 Enkephalin 60 REVLIMID ® 60 chronic lymphocytic leukemia CLL 60 Loramyc R 60 paclitaxel Taxol ® 60 telbivudine 60 oral fludarabine 60 docetaxel Taxotere ® 60 DXL# 60 Rebif ® 60 STELARA 60 Rhucin R 60 Phase IIb trials 60 interferon beta 1b 60 mitoxantrone 60 receptor tyrosine kinase inhibitor 60 docetaxel Taxotere 60 EndoTAGTM 1 60 thalidomide Thalomid 60 Cimzia ® certolizumab pegol 60 BRIM3 60 panitumumab Vectibix 60 AEG# 60 JAK1 60 ZACTIMA 60 MOZOBIL 60 herpetic keratitis 60 FavId 60 bortezomib 60 Genz # 60 RGB # 60 cinacalcet HCl 60 Epratuzumab 60 febuxostat 60 Tavocept 60 PROSTVAC TM 60 ZOLINZA 60 TEMODAL 60 Arixtra 60 pegloticase 60 RhuDex ® 60 Cimzia TM 60 orBec 60 hA# 60 Vidaza 60 PF # [001] 60 Interferon alpha 60 peginterferon alfa 2b 60 Sprycel dasatinib 60 elesclomol 60 active comparator 60 Hycamtin 60 mRCC 60 icatibant 60 placebo controlled clinical 60 Annamycin 60 Blinatumomab 60 Betaferon ® 60 phase 2a 60 CLARITY study 60 plus dexamethasone 60 Nexavar 60 relapsing multiple sclerosis 60 alkylating agent 60 ascending doses 60 ASONEP 60 SAR# [004] 60 mifamurtide 60 TG# [001] 60 ritonavir boosted 60 huN# DM1 60 Phase 2a 60 Panzem R 60 rNAPc2 60 darapladib 60 refractory APL 60 Xanafide 60 gemcitabine chemotherapy 60 cell lymphoma CTCL 60 EGFR expressing mCRC 60 DOXIL 60 lixisenatide 60 Phase IIb 60 Evoltra R 60 Pixantrone 60 Augment Injectable 60 ELND# 60 MGd 60 Onco TCS 60 anti leukemic 60 Evoltra ® 60 AEGR 60 MabThera 60 Ventavis 60 ISENTRESS 59 abatacept 59 AzaSite Plus 59 HoFH 59 dosing cohort 59 pharmacodynamic 59 Arzerra 59 LY# [003] 59 assessing T DM1 59 Nuvion 59 Golimumab 59 abatacept Orencia 59 bortezomib Velcade R 59 dose escalation study 59 cariprazine 59 Locteron 59 RAPTIVA 59 AVINZA 59 pegylated interferon alpha 59 apaziquone 59 XELOX 59 ProSavin 59 volociximab 59 Arzerra ofatumumab 59 sorafenib Nexavar ® 59 metastatic CRPC 59 REVLIMID R 59 tezampanel 59 Mepact 59 initiate Phase 1b 59 fenofibric acid 59 IRX 2 59 oxymorphone ER 59 mipomersen 59 INTERCEPT platelets 59 SEBIVO 59 metastatic HRPC 59 TroVax ® 59 MEK inhibitor 59 Theratope 59 milatuzumab 59 iniparib 59 RSD# 59 Exherin TM 59 follicular non 59 virus HCV protease inhibitor 59 TRIOLEX 59 USL# 59 FIRMAGON R 59 voclosporin 59 visilizumab 59 Arranon 59 sorafenib Nexavar R 59 THALOMID 59 GW# [003] 59 Androxal TM 59 AGGRASTAT R 59 Halaven 59 IND submission 59 Copegus ribavirin 59 temozolomide 59 ACTEMRA TM 59 selective androgen receptor modulator 59 Mozobil 59 Removab 59 Cloretazine ® 59 Clonicel 59 refractory chronic lymphocytic 59 PEP# [003] 59 Allovectin 7 R 59 Archexin 59 placebo controlled Phase III 59 Santhera 59 PNP inhibitor 59 Zalbin 59 Plenaxis R 59 Capesaris 59 boosted protease inhibitor 59 RDEA# 59 olaparib 59 CANCIDAS 59 evaluating satraplatin 59 temsirolimus 59 recurrent glioblastoma multiforme 59 subcutaneously administered 59 GRN#L 59 SCH # 59 infliximab 59 Azixa 59 glatiramer acetate 59 HSP# inhibitor 59 Aloxi injection 59 paclitaxel Taxol R 59 TKM ApoB 59 Plenaxis TM 59 relapsed MCL 59 Dasatinib 59 oral rivaroxaban 59 JANUVIA 59 Ocrelizumab 59 DASISION 59 motesanib 59 LCP AtorFen 59 anakinra 59 Gleevec Glivec 59 BENLYSTA ® 59 antitumor activity 59 IAP inhibitors 59 relapsed refractory aggressive 59 bosutinib 59 Vectibix panitumumab 59 Certican 59 MyVax R 59 refractory gout 59 CINOD 59 Phase 1a 59 lorvotuzumab mertansine 59 PEGylated interferon beta 1a 59 CRMD# 59 Vandetanib 59 blinded randomized placebo controlled 59 leukemia CLL 59 cutaneous T 59 degarelix 59 Q#IR 59 oral methylnaltrexone 59 Civacir 59 RoACTEMRA 59 CAELYX 59 Viprinex 59 ACZ# 59 depsipeptide 59 oral antiviral 59 GRN# 59 forodesine hydrochloride 59 metaglidasen 59 Xyrem ® 59 FOLFOX 59 alemtuzumab 59 Pixuvri 59 TMC# [001] 59 plus DOXIL 59 HspE7 59 gemcitabine Gemzar ® 59 INTEGRILIN 59 dose cohort 59 IMC A# 59 GATTEX 59 midstage clinical 59 Triolex 59 palifosfamide 59 pediatric acute lymphoblastic 59 Æterna Zentaris 59 OHR/AVR# 59 cetuximab 59 APOPTONE 59 tezampanel NGX# 59 NOXAFIL 59 MAXY G# 59 R sorafenib tablets 59 Phase IIb clinical trials 59 nalbuphine ER 59 pegylated liposomal doxorubicin 59 lenalidomide 59 APTIVUS 59 Trastuzumab 59 Gabapentin GR 59 ongoing Phase 1b 59 Laquinimod 59 MIRCERA 59 TACI Ig 59 YONDELIS R 59 GVAX immunotherapy 59 oral salmon calcitonin 59 peginesatide 59 Evoltra 59 FIRAZYR 59 Phase IIb trial 59 metastatic castration resistant 59 Romidepsin 59 cetuximab Erbitux 59 tolerability 59 masitinib 59 NUVIGIL 59 Pegasys plus Copegus 59 rFIXFc 59 cetuximab Erbitux R 59 Campath alemtuzumab 59 Vicinium TM 59 pitavastatin 59 ARCALYST 59 Pertuzumab 59 Irinotecan 59 telaprevir VX 59 metastatic renal cell carcinoma 59 #mg/m# [001] 59 riociguat 59 INTELENCE 59 sustained virologic response 59 HCV protease inhibitor 59 #D#C# 59 dasatinib Sprycel ® 59 FluCAM 59 Androxal 59 gefitinib 59 ACAPODENE 59 REYATAZ R 59 certolizumab 59 Avastin bevacizumab 59 Quinamed 59 Prestara 59 Defibrotide 59 PCK# 59 BLA filing 59 pexiganan 59 CYC# 59 metastatic colorectal cancer 59 HCV SPRINT 59 cisplatin vinorelbine 59 docetaxel 59 CBLC# 59 Revimmune 59 AMEVIVE 59 alefacept 59 COPAXONE ® 59 Diamyd ® 59 lymphoma CTCL 59 daptomycin 58 Promacta 58 Catena ® 58 REVLIMID lenalidomide 58 ceftazidime 58 Sulonex TM 58 TOLAMBA 58 Natalizumab 58 Phase #b/#a trial 58 tesetaxel 58 farletuzumab 58 Aromasin 58 Cloretazine R 58 Phase 2a clinical 58 XGEVA 58 angiogenesis inhibitor 58 novel histone deacetylase 58 erlotinib Tarceva ® 58 nucleoside analog 58 Personalized Immunotherapy 58 PREZISTA r 58 Pegasys ® 58 Icatibant 58 #I TM# 58 PS# [001] 58 relapsing MS 58 BCIRG 58 lintuzumab SGN 58 irbesartan 58 clinical pharmacology studies 58 antibody MAb 58 Huntexil 58 desvenlafaxine succinate 58 preclinically 58 PREOS 58 refractory AML 58 ADAGIO study 58 Tyrima 58 VNP#M 58 PREOS R 58 MT# MEDI 58 dose dose escalation 58 Tekturna HCT 58 randomized controlled Phase 58 Raptiva ® 58 hematological cancers 58 Chemophase 58 Telatinib 58 APF# 58 multicenter Phase II 58 double blinded placebo 58 Triapine R 58 radiation sensitizer 58 evaluating REVLIMID 58 Benlysta belimumab 58 Raptiva R 58 relapsed SCLC 58 Asentar 58 tafamidis 58 Noxafil 58 ancrod 58 chronic myeloid leukemia CML 58 Carfilzomib 58 interferon gamma 1b 58 Pemetrexed 58 PLK1 SNALP 58 AZD# 58 anti CTLA 58 anticancer compound 58 belatacept 58 hematologic malignancies 58 mg kg dose 58 Phase IIa 58 bevacizumab Avastin 58 ARIKACE ™ 58 Phase Ib clinical trials 58 GALNS 58 MAXY alpha 58 PEGylated Fab fragment 58 systemic ALCL 58 Luteinizing Hormone Releasing Hormone 58 Onconase 58 carboplatin 58 PHX# 58 Pegasys peginterferon alfa 2a 58 vascular disrupting agent 58 LHRH antagonists 58 Argatroban 58 Phase III 58 Neuradiab 58 pemetrexed Alimta 58 Aptivus 58 dalbavancin 58 NGX# 58 oblimersen 58 GSK# [001] 58 microplasmin 58 BCR ABL inhibitor 58 investigational hepatitis C 58 ZENPEP 58 Azilect ® 58 Ilaris 58 trastuzumab Herceptin 58 recurrent glioblastoma 58 Bortezomib 58 Phase III pivotal 58 ALGRX 58 maximally tolerated dose 58 Hycamtin ® 58 mTOR inhibitor 58 VEGF Trap 58 Teysuno 58 relapsed CLL 58 alemtuzumab Campath 58 OMP #M# 58 OPAXIO 58 pharmacokinetic PK study 58 ThermoDox ® 58 refractory PTCL 58 vinflunine 58 ONCONASE 58 everolimus tablets 58 silodosin 58 SCCHN 58 G CSF 58 Orazol 58 rituximab Rituxan 58 elagolix 58 vernakalant oral 58 #mg BID [001] 58 uric acid lowering 58 HepeX B 58 Ceplene/IL-2 58 randomized Phase IIb 58 lubiprostone 58 platinum refractory 58 telaprevir 58 Actilon 58 Desmoteplase 58 Pazopanib 58 WILEX 58 GED aPC 58 oritavancin 58 investigational therapies 58 cabazitaxel 58 cathepsin K inhibitor 58 evaluating Actimmune 58 VIDAZA 58 Taxotere docetaxel 58 apremilast 58 Navelbine ® 58 ezogabine 58 Aclasta 58 Phase #/#a trial 58 Myocet 58 crizotinib PF # 58 eritoran 58 Arcalyst 58 epigenetic therapies 58 estramustine 58 vilazodone 58 vernakalant 58 davunetide 58 oxaliplatin Eloxatin 58 systemic anaplastic large 58 acyclovir Lauriad ® 58 castrate resistant prostate cancer 58 XL# SAR# 58 UPLYSO 58 capecitabine Xeloda R 58 OncoGel 58 plus prednisone 58 AVADO 58 ruxolitinib 58 TASQ 58 pexelizumab 58 Tanespimycin 58 leading oral taxane 58 orphan designation 58 tramiprosate ALZHEMED TM 58 HUMIRA 58 oral diclofenac 58 liposomal formulation 58 cetuximab Erbitux ® 58 QUADRAMET 58 Exforge HCT 58 OMP #R# 58 Aplidin R 58 BLA submission 58 BENLYSTA 58 Cinryze TM 58 metastatic sarcomas 58 casopitant 58 Rituxan rituximab 58 dose regimens 58 Rhucin ® 58 Panitumumab 58 Oracea 58 lapatinib Tykerb 58 HQK 58 treatment naive genotype 58 TLK# 58 irinotecan 58 registrational trials 58 Dacogen decitabine 58 PEG INTRON 58 ospemifene 58 pegylated interferon alfa 2a 58 metastatic castrate resistant 58 lupus nephritis 58 mixed dyslipidemia 58 LibiGel ® 58 CD# monoclonal antibody 58 Factor VIIa 58 JAK inhibitors 58 EDEMA3 58 Doxil ® 58 YERVOY 58 erlotinib 58 glatiramer 57 dirucotide MBP# 57 Cetrorelix 57 Omacetaxine 57 CCX# 57 Fx #A 57 anti EGFR antibody 57 AGILECT R 57 Increlex TM 57 REMINYL ® 57 IMC #B 57 SIMPONI 57 oral Xeloda 57 oral anticoagulant 57 BrachySil TM 57 cyclophosphamide doxorubicin vincristine 57 ProLindac 57 talabostat 57 urocortin 2